N THE U.S. PATENT AND TRADEMARK OFFICE

Ib 16 patents

In re Application of:

Docket No. 05213-0852 (43170-263550)

 $f_i^1$ 

AGOSTON ET AL.

Serial No. 09/939,208

Filed:

August 24, 2001

For:

**ANTIANGIOGENIC AGENTS** 

Transmitted herewith is a paper in the above-identified application.

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

_ ~	 1: 4: 1 2:	7.O.E.D. 61.O	01 07 1 . 1	.1.17.1 1.1	٠ .

Ш	Small entity status of this application under 37 C.F.R. $\S1.9$ and $\S1.27$ has been established by a verified	t
	statement.	

3-mth extension of time.

No additional fee is required.

The additional fee is calculated as shown below:

					SMALL ENTITY		OTHER T	<del> ·</del>
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT. FEE	RATE	ADDIT. FEE
TOTAL	4	MINUS	92=	0	x9	\$	x18	\$
INDEP.	2	MINUS	3=	0	x43	\$	x86	\$
FIRST PRESENTATION OF  MULTIPLE DEPENDENT CLAIMS					+145	\$	+290	\$
		TOTAL ADDITIONA	AL FEE	\$		<b>\$</b> 0		

A check in the amount of \$950 is attached.

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16, or credit any overpayment, to Account No. 11-0855. A duplicate copy of this sheet is enclosed.

I hereby certify that this correspondence is being deposited with with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents,

Signature

KILPATRICK STOCK ON LEP

1100 Peachtree Street Suite 2800

Atlanta, Georgia 303 9-4530

Telephone: 404/815/6500

Robert E. Richards, Attorney for Applicant

Reg. No. 29,105